NextPlat (NXPL) Preferred Stock Liabilities (2010 - 2011)
NextPlat's (NXPL) quarterly Preferred Stock Liabilities came in at $6.9 million in Q3 2011, down 54.04% quarter-over-quarter from $15.1 million in Q2 2011.
Powered by 
Analysis
NextPlat (NXPL) Preferred Stock Liabilities (2010 - 2011) Analysis & Trends
NextPlat (NXPL) has reported Preferred Stock Liabilities for 2 consecutive years, with $6.9 million the latest figure, recorded in Q3 2011.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $6.9 million in Q3 2011; TTM through Sep 2011 was $6.9 million, a N/A change from a year earlier, with the FY2010 full-year figure at $6.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $6.9 million for Q3 2011 at NextPlat, down from $15.1 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $15.1 million in Q2 2011 and troughed at $6.7 million in Q4 2010.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | - |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | - |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | - |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | - |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | - |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | - |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | - |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | - |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2011 | 6.92 Mn |
| Jun 30, 2011 | 15.06 Mn |
| Dec 31, 2010 | 6.71 Mn |